These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 24731771)

  • 1. Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria.
    Silva PM; Costa AC; Mendes A; Barbosa MP
    Allergol Immunopathol (Madr); 2015; 43(2):168-73. PubMed ID: 24731771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
    Metz M; Ohanyan T; Church MK; Maurer M
    J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic autoimmune urticaria with omalizumab.
    Kaplan AP; Joseph K; Maykut RJ; Geba GP; Zeldin RK
    J Allergy Clin Immunol; 2008 Sep; 122(3):569-73. PubMed ID: 18774392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligelizumab for Chronic Spontaneous Urticaria.
    Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
    N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life experiences with omalizumab for the treatment of chronic urticaria.
    Sussman G; Hébert J; Barron C; Bian J; Caron-Guay RM; Laflamme S; Stern S
    Ann Allergy Asthma Immunol; 2014 Feb; 112(2):170-4. PubMed ID: 24468258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population.
    Kulthanan K; Tuchinda P; Chularojanamontri L; Likitwattananurak C; Ungaksornpairote C
    J Dermatolog Treat; 2017 Mar; 28(2):160-165. PubMed ID: 27388043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
    Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
    Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
    Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria.
    Song CH; Stern S; Giruparajah M; Berlin N; Sussman GL
    Ann Allergy Asthma Immunol; 2013 Feb; 110(2):113-7. PubMed ID: 23352531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy.
    Casale TB; Bernstein JA; Maurer M; Saini SS; Trzaskoma B; Chen H; Grattan CE; Gimenéz-Arnau A; Kaplan AP; Rosén K
    J Allergy Clin Immunol Pract; 2015; 3(5):743-50.e1. PubMed ID: 26054553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty-five patients.
    Türk M; Yılmaz İ; Bahçecioğlu SN
    Allergol Int; 2018 Jan; 67(1):85-89. PubMed ID: 28566225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
    Rottem M; Segal R; Kivity S; Shamshines L; Graif Y; Shalit M; Kessel A; Panasoff J; Cohen S; Toubi E; Agmon-Levin N
    Isr Med Assoc J; 2014 Aug; 16(8):487-90. PubMed ID: 25269339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term management of chronic spontaneous urticaria with omalizumab.
    Pinto Gouveia M; Gameiro A; Pinho A; Gonçalo M
    Clin Exp Dermatol; 2017 Oct; 42(7):735-742. PubMed ID: 28649751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
    Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
    J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature.
    Tonacci A; Billeci L; Pioggia G; Navarra M; Gangemi S
    Pharmacotherapy; 2017 Apr; 37(4):464-480. PubMed ID: 28226418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
    Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K
    J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab for the treatment of chronic urticaria.
    Zuberbier T; Maurer M
    Expert Rev Clin Immunol; 2015 Feb; 11(2):171-80. PubMed ID: 25566680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: A retrospective study.
    Serarslan G; Uzun M; Doğramacı AÇ; Çelik E
    Dermatol Ther; 2019 Jan; 32(1):e12752. PubMed ID: 30238582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.